Results 101 to 110 of about 61,140,294 (163)

Impact of proper surgical treatment on the survival of patients with epithelial ovary cancer. [PDF]

Rev Col Bras Cir, 2022
Faria FH, Lage APD, Rodrigues AN, Wainstein AJA.   +3 more
europepmc   +1 more source

Female Infertility: Cardiovascular Disease Risk Factor or Marker of a Population at Cardiovascular Risk? [PDF]

Arq Bras Cardiol
Rivera MAM, Rivera IR, Oliveira GMM.
europepmc   +1 more source

[PAPPS Expert Groups. Cancer prevention recommendations: Update 2022]. [PDF]

Aten Primaria, 2022
Marzo-Castillejo M, Bartolomé-Moreno C, Bellas-Beceiro B, Melús-Palazón E, Vela-Vallespín C.   +4 more
europepmc   +1 more source

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer. [PDF]

Future Oncol
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melou AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Liu X, Nieuwenhuysen EV, DUO-E Investigators.   +29 more
europepmc   +1 more source

Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study "Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer": The International NOGGO, ENGOT, and GCIG Survey. [PDF]

Cancers (Basel)
Dimitrova D, Samartzis EP, Zocholl D, Barretina-Ginesta MP, Leitner K, Havelka P, Achimas-Cadariu P, Taskiran C, Mittelstadt S, Van Nieuwenhuysen E, Bauerschmitz G, Heinzelmann-Schwarz V, Madariaga A, Ringsdorf U, Zwimpfer T, Madroñal C, Enzinger HM, Al Rubaish S, Sehouli J, Woopen H.   +19 more
europepmc   +1 more source

FRECUENCIA DE LA MUTACIÓN BRCA1/BRCA2 EN CÁNCER DE OVARIO Y USO DE INHIBIDORES PPAR

El cáncer de ovario, es la segunda causa de cáncer ginecológico en Estados Unidos, y la primera causa de muerte por cáncer ginecológico en ese país. En Venezuela, es la tercera causa de cáncer ginecológico, aportando cifras más bajas de mortalidad.
Borga, Guillermo, Salazar, Héctor, Sucre, Carlos, Vivas, Liliam   +3 more
core   +1 more source

Letter to the Editor about “Preoperative neutrophil/ lymphocyte ratio as prognostic factor in epitelial ovarian cancer” [PDF]

Rev Colomb Obstet Ginecol
Cesar Huamanciza LÁ.
europepmc   +1 more source

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. [PDF]

Br J Cancer, 2023
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A, INOVATYON study group.   +41 more
europepmc   +1 more source

[Hidradenitis Suppurativa: Most Relevant Epidemiological Characteristics of an Underdiagnosed Disease. A Cross-Sectional Study] [PDF]

Rev Fac Cien Med Univ Nac Cordoba
Abeledo LS, Montes MV, Lombardo V, Guthmann K, Caramés M, Aguirre S, Busso C.   +6 more
europepmc   +1 more source

La reutilización de biomarcadores para otros fines: oportunidades y dificultades en el cambiante campo de la medicina de laboratorio. [PDF]

Adv Lab Med
Gruson D, Menghoun N, Pouleur AC, Bayes Genis A.   +3 more
europepmc   +1 more source